---
layout: minimal-medicine
title: Vinorelbine
---

# Vinorelbine
### Generic Name
Vinorelbine

### Usage
Vinorelbine is a chemotherapy medication primarily used to treat various types of cancer.  Its main application is in the treatment of non-small cell lung cancer (NSCLC), both as a single agent and in combination with other chemotherapy drugs like cisplatin.  It's often a first-line treatment option for metastatic NSCLC.  

Beyond NSCLC, vinorelbine finds use in treating several other cancers, though often as an off-label treatment (meaning it's not officially approved by regulatory bodies for these specific uses, but is sometimes prescribed by oncologists based on clinical experience and research):  These include breast cancer (metastatic), Hodgkin lymphoma (relapsed or refractory), malignant pleural mesothelioma, cervical cancer, ovarian cancer (relapsed), salivary gland cancer (recurrent), small cell lung cancer (refractory), and soft tissue sarcoma (advanced).  The specific use and efficacy of vinorelbine in these cancers vary considerably and are highly dependent on individual patient factors and the specific treatment regimen employed.  Always consult with an oncologist to determine the appropriateness of vinorelbine for a specific cancer diagnosis.


### Dosage

Vinorelbine dosage is highly individualized and depends on several factors, including the type of cancer, the patient's overall health, other medications being taken, and the method of administration (intravenous [IV] or oral).  The information below is for illustrative purposes only and should not be considered medical advice.  Dosage is always determined and adjusted by a qualified oncologist.

**Adult Dosage (IV):**

* **NSCLC (in combination with cisplatin):** 25 mg/m² on days 1, 8, 15, and 22 of a 28-day cycle, or 30 mg/m² once a week.
* **Metastatic NSCLC (single agent):** 30 mg/m² once a week.
* **Other Cancers (off-label uses):** Dosage varies widely depending on the specific cancer and treatment regimen.


**Adult Dosage (Oral):**

* **NSCLC (single agent):** Initial dose: 60 mg/m² every 7 days for 3 doses (maximum initial dose: 120 mg weekly).  If tolerated, the dose may be increased to 80 mg/m² every 7 days starting with the fourth dose (maximum dose: 160 mg weekly).
* **Metastatic Breast Cancer (single or combination therapy):** Dosage varies depending on the treatment plan.

**Pediatric Dosage:** Vinorelbine is used in children and adolescents for specific cancers (like refractory or recurrent Hodgkin lymphoma and leukemias), but the dosage is significantly different and strictly determined by a pediatric oncologist based on body surface area (BSA) or weight.


**Dosage Adjustments:**  Dosage adjustments are frequently necessary based on factors such as hepatic (liver) and renal (kidney) function, body weight, and the occurrence of side effects.  These adjustments are made by a healthcare professional.

**Important Note:**  The dosage information above is a summary. Precise dosing and scheduling must be determined by a qualified healthcare professional based on individual patient needs.


### Side Effects

Vinorelbine, like other chemotherapy drugs, can cause a range of side effects. The severity and frequency of these side effects vary from person to person.

**Common Side Effects (>10%):**

* Neurotoxicity (nerve damage), including peripheral neuropathy (numbness, tingling, pain in hands and feet)
* Nausea and vomiting
* Constipation and diarrhea
* Hair loss (alopecia)
* Neutropenia (low white blood cell count, increasing infection risk)
* Leukopenia (low white blood cell count)
* Anemia (low red blood cell count)
* Elevated liver enzyme levels
* Injection site reactions (pain, inflammation)
* Weakness (asthenia)
* Elevated creatinine levels (kidney function indicator)

**Less Common but Serious Side Effects (1-10% or less frequent):**

* Severe neutropenia (leading to serious infections)
* Thrombocytopenia (low platelet count, increasing bleeding risk)
* Febrile neutropenia (fever with low white blood cell count)
* Hepatotoxicity (liver damage)
* Pulmonary toxicity (lung damage)
* Severe allergic reactions
* Intestinal complications (obstruction, perforation)
* Bone marrow suppression



If any adverse effects occur, especially severe or concerning ones, it is crucial to contact a healthcare provider immediately.


### How it Works

Vinorelbine is a vinca alkaloid, a type of chemotherapy drug. It works by interfering with the cell's ability to divide and replicate.  Specifically, it binds to tubulin, a protein that forms microtubules – essential components of the cell's internal structure crucial for cell division. By disrupting microtubule formation, vinorelbine prevents cells from dividing properly, ultimately leading to their death. This effect is particularly pronounced in cancer cells, which divide rapidly.  In addition, vinorelbine may interfere with the synthesis of nucleic acids and proteins, further hindering cancer cell growth and survival.


### Precautions

* **Pregnancy and Breastfeeding:** Vinorelbine is categorized as a pregnancy category D drug, meaning it poses a risk to the developing fetus.  Women of reproductive age should use effective contraception during treatment and for several months afterward. Breastfeeding should be avoided during and after treatment.
* **Liver and Kidney Function:** Vinorelbine is metabolized by the liver and excreted by the kidneys.  Patients with impaired liver or kidney function may require dose adjustments to minimize the risk of adverse effects.
* **Bone Marrow Suppression:**  Vinorelbine can cause severe bone marrow suppression, leading to decreased white blood cell, red blood cell, and platelet counts. This increases the risk of infection, anemia, and bleeding. Close monitoring of blood counts is essential.
* **Other Medications:**  Vinorelbine can interact with various other medications.  It's crucial to inform your healthcare provider about all medications, including over-the-counter drugs, herbal remedies, and supplements.
* **Infusion Site:** During intravenous administration, extravasation (leakage of the drug into surrounding tissues) should be avoided.  Proper technique and immediate action are required if extravasation occurs.


### FAQs

* **Q: How long will I need to take vinorelbine?** A: The duration of treatment with vinorelbine depends on the type and stage of cancer, the treatment response, and the occurrence of side effects.  Your oncologist will determine the appropriate treatment duration.

* **Q: How is vinorelbine stored?** A: Storage instructions vary depending on the formulation (IV or oral). Follow the specific storage instructions provided by your pharmacist.

* **Q: What should I do if I miss a dose?** A: Contact your oncologist or healthcare provider immediately if you miss a dose.  Do not attempt to adjust the dosage yourself.

* **Q: Are there any long-term side effects?** A:  Some long-term side effects are possible, such as peripheral neuropathy.  Regular follow-up appointments with your healthcare provider are essential for monitoring and managing potential long-term effects.

* **Q: Can I drive while taking vinorelbine?** A:  Driving may be affected by side effects like fatigue, nausea, and neurotoxicity. Follow your healthcare provider's advice on driving while undergoing treatment.


**Disclaimer:** This information is for educational purposes only and is not a substitute for professional medical advice. Always consult with a healthcare provider or oncologist before starting any new medication, especially chemotherapy drugs like vinorelbine.  They can assess your individual health status, determine the appropriate dosage, and monitor for potential side effects.
